drugset
drugset / Trial / NCT07536061

A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

NCT07536061 ↗

Phase 1 Recruiting 32 enrolled Sarepta Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).

Timeline

Start
2026-05-12
Primary completion
2027-11-30
Completion
2027-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SRP-1005 Unknown — Subcutaneous

Indications

Huntington disease